Menu
Talem Therapeutics is focused on the discovery and development of therapeutic antibodies targeting emerging, infectious diseases, neurology, immuno-oncology, inflammation, and rare/specialty diseases.
With direct access to world-class, expedited and end-to-end technologies in the antibody discovery and development process, Talem accelerates novel, therapeutic antibody treatments to the clinic through strategic alliances and partnerships. For further information contact bd@talemtherapeutics.com.
Talem Therapeutics (Talem) is a wholly owned subsidiary of ImmunoPrecise Antibodies (IPA) and is focused on the discovery and development of next-generation, fully human, monoclonal, therapeutic antibodies to target multiple disease indications.
Using the proprietary antibody discovery platforms and innovative technologies housed at ImmunoPrecise Antibodies and U-Protein Express (an IPA company), Talem aims to accelerate novel, high-value, therapeutic antibody treatments to the clinic.
We have optimized our powerful, custom, species-agnostic technologies for use with transgenic animal platforms to enable the discovery of highly diverse, fully human antibodies with superior clinical safety and efficacy as well as the lowest immunogenicity. The ability to select very specific, “needle-in-a-haystack” human antibodies via this advanced combination offers an entirely new avenue of therapeutic antibody discovery. Talem is the only CRO affiliate globally to offer these services as a partnership with OmniAb transgenic (www.omniab.com) animals using their own license.
Talem Therapeutics has been actively involved in COVID-19 research since January 2020. Monoclonal antibodies were derived from several animal species, including transgenic Omnirats® animals, rabbits, llama, and human, to access a broad epitope coverage. We exploit multiple antibody formats, valency, and size to select antibodies against multiple/rare epitopes. In a multi-national effort, involving our scientists in North America and Europe, Talem has now developed a rich and diverse discovery portfolio of SARS-CoV-2 candidate antibodies yielding epitope and functional diversity.
Talem Therapeutics is focused on the discovery and development of next-generation, fully human, monoclonal, therapeutic antibodies targeted toward any disease indication.
With direct access to world-class, expedited and end-to-end technologies in antibody discovery, characterization, manufacturing and engineering, Talem accelerates novel, therapeutic antibody treatments to the clinic through strategic alliances and partnerships.
For Business Development or Partnering Opportunities
bd@talemtherapeutics.com
One Broadway, 14th floor
Cambridge, MA 02142, USA
For Investor Inquiries
Frédéric Chabot
fchabot@immunoprecise.com
© 2020 All Rights Reserved